Strategic Blueprint LLC Invests $201,000 in Novo Nordisk A/S (NYSE:NVO)

Strategic Blueprint LLC acquired a new position in Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, HoldingsChannel reports. The firm acquired 1,942 shares of the company’s stock, valued at approximately $201,000.

A number of other large investors also recently modified their holdings of the company. IHT Wealth Management LLC raised its holdings in shares of Novo Nordisk A/S by 3.5% in the 4th quarter. IHT Wealth Management LLC now owns 2,369 shares of the company’s stock worth $321,000 after purchasing an additional 80 shares during the period. Hancock Whitney Corp raised its holdings in shares of Novo Nordisk A/S by 4.1% during the 1st quarter. Hancock Whitney Corp now owns 2,342 shares of the company’s stock valued at $373,000 after buying an additional 92 shares during the period. SRS Capital Advisors Inc. raised its holdings in shares of Novo Nordisk A/S by 9.6% during the 1st quarter. SRS Capital Advisors Inc. now owns 1,060 shares of the company’s stock valued at $169,000 after buying an additional 93 shares during the period. Relyea Zuckerberg Hanson LLC raised its holdings in shares of Novo Nordisk A/S by 3.2% during the 4th quarter. Relyea Zuckerberg Hanson LLC now owns 3,159 shares of the company’s stock valued at $327,000 after buying an additional 99 shares during the period. Finally, Fort Washington Investment Advisors Inc. OH raised its holdings in shares of Novo Nordisk A/S by 3.5% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 2,960 shares of the company’s stock valued at $306,000 after buying an additional 100 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NVO has been the topic of several analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Monday, April 1st. UBS Group initiated coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating on the stock. BMO Capital Markets initiated coverage on Novo Nordisk A/S in a report on Friday. They set an “outperform” rating and a $163.00 target price on the stock. Finally, Morgan Stanley began coverage on Novo Nordisk A/S in a report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price on the stock. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Price Performance

NVO stock opened at $124.52 on Friday. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19. Novo Nordisk A/S has a 52-week low of $75.56 and a 52-week high of $138.28. The stock’s 50 day moving average is $125.93 and its two-hundred day moving average is $109.61. The company has a market capitalization of $558.79 billion, a PE ratio of 46.03, a P/E/G ratio of 2.09 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.05. The company had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. Analysts predict that Novo Nordisk A/S will post 3.33 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were given a $0.664 dividend. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date of this dividend was Friday, March 22nd. This represents a dividend yield of 0.9%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 49.17%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.